Science & ResearchJul 27, 2026
Longitudinal plasma proteomics predict phenoconversion to clinically manifest ALS.
The study of pre-symptomatic amyotrophic lateral sclerosis (ALS) and the design of disease prevention trials are greatly hampered by our inability to predict which unaffected carriers of ALS-associated pathogenic variants will phenoconve…
The study of pre-symptomatic amyotrophic lateral sclerosis (ALS) and the design of disease prevention trials are greatly hampered by our inability to predict which unaffected carriers of ALS-associated pathogenic variants will phenoconvert to clinically manifest disease and…
Sign in to learn & save →
The frontier is open to all. Sign in to learn this from first principles and save it to your knowledge base.